Back to search

Peptide record

TPDB77255

LFchimera Anticancer modified_plain modified
37 amino acids
Basic Information
TPDB77255
LFchimera
Anticancer
Cancer-related peptides
CancerPPD 2.0
modified_plain
Yes
A 37-aa modified anticancer peptide sequence curated from CancerPPD 2.0, without an available 3D structural model.
C-terminal: Amidation
Sequence
FKCRRWQWRMKKLG-K-RSKNKGFKEQAKSLLKWILD-NH2
Physicochemical Analysis
C203H330N62O45S2
HPTYV
K
4423.36
11.65
13
2
12
+11
6.26
-1.195
55.41
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
16500
373.02
6
Residue Composition
number
1
A
4
R
1
N
1
D
1
C
1
E
2
Q
2
G
0
H
1
I
4
L
9
K
1
M
2
F
0
P
2
S
0
T
3
W
0
Y
0
V
Amino Acid Distribution
A: 1 R: 4 N: 1 D: 1 C: 1 E: 1 Q: 2 G: 2 H: 0 I: 1 L: 4 K: 9 M: 1 F: 2 P: 0 S: 2 T: 0 W: 3 Y: 0 V: 0
Chemical Descriptors
37
C203H330N62O45S2
4423.36
11.65
+11
6.26
-1.195
Amidation
L
Linear
Free
Antimicrobial
Synthetic - Lectoferrin chimera
Evidence Records 2 records
Evidence 1 Activity

Activity

cell viability
cell viability ~ 44% at 10 µM
Anticancer
~44 % at 10 µM

Target

Liver Cancer
HepG-2
Liver

Assay & Model

MTT assay
12-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2023

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

cell viability
cell viability ~ 8% at 20 µM
Anticancer
~8 % at 20 µM

Target

Blood Cancer
Jurkat
Blood

Assay & Model

MTT assay
6-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2023